Usual Adult Dose for Anthrax Prophylaxis

Pre-Exposure Prophylaxis:
Primary series: 0.5 mL intramuscularly at 0, 1, and 6 months
Booster series: 0.5 mL intramuscularly 6 and 12 months after primary series and at 12-month intervals thereafter

Pre-Exposure Prophylaxis in patients at risk of hematoma from intramuscular injection:
Primary series: 0.5 mL subcutaneously at 0, 2, and 4 weeks and 6 months
Booster series: 0.5 mL subcutaneously 6 and 12 months after primary series and at 12-month intervals thereafter

Post-Exposure Prophylaxis:
Primary series: 0.5 mL subcutaneously at 0, 2, and 4 weeks post-exposure combined with antimicrobial therapy

Comments:

• Efficacy for post-exposure prophylaxis is based solely on animal models of inhalation anthrax.
• The optimal catch up schedule for missed or delayed booster doses is unknown.

• Active immunization of patients aged 18 to 65 for pre-exposure prophylaxis in those at high risk of exposure
• Active immunization of patients aged 18 to 65 for post-exposure prophylaxis after suspected or confirmed Bacillus anthracis exposure, administered in conjunction with recommended antibacterials

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Severe hypersensitivity (e.g. anaphylaxis) to any of the ingredients

Dialysis

Data not available

Other Comments

Administration advice:

• Administer pre-exposure prophylaxis intramuscularly into the deltoid or subcutaneously over the deltoid.
• Administer post-exposure prophylaxis subcutaneously over the deltoid.
• The vial stopper contains natural rubber latex which can cause allergic reactions in patients sensitive to latex.

• Refrigerate; do not freeze

• Shake thoroughly to ensure a homogenous suspension during withdrawal.

• Do not mix with other products in the syringe